AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Drug Giant Roche Buys Former Google Execs' Flatiron in $1.9B Deal February 15, 2018 China Biologic Products Announces Effectiveness Of Registration Statement And Mailing Of Definitive Proxy Statement/Prospectus For 2017 Annual Meeting Of Stockholders May 21, 2017 SPR Therapeutics Promotes To SVP Of Research And Development September 6, 2017
China Biologic Products Announces Effectiveness Of Registration Statement And Mailing Of Definitive Proxy Statement/Prospectus For 2017 Annual Meeting Of Stockholders May 21, 2017
